Protein

Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards

7 days ago   |   By Xconomy

This year's Lasker Awards, the US's most prestigious biomedical honor, are going to five scientists whose work led to a critical breast cancer treatment and significant basic research advances that have helped pave the way for immunotherapy. H. Michael Shepard, Dennis Slamon, and Axel Ullrich won the Lasker-DeBakey Clinical Medical Research Award for inventing trastuzumab , the Genentech antibody drug for HER2-positive breast cancer, a form of the disease that afflicts more than 50,000 women each year. Herceptin is the first monoclonal antibody to target a cancer-causing protein-HER2...
Read more ...

 


Search by Tags

   Protein      Cancer      Research      BioMedical      Clinical      Immunology      Biomedical      Drugs      Drug      Boston blog main      Boston top stories      Boulder      Denver blog main      Denver top stories      Detroit blog main      Detroit top stories      Indiana blog main      Indiana top stories      National      National blog main      National top stories      New York blog main      New York top stories      Raleigh-Durham blog main      Raleigh-Durham top stories      San Diego blog main      San Diego top stories      San Francisco blog main      San Francisco top stories      Seattle blog main      Seattle top stories      Texas blog main      Texas top stories      Wisconsin blog main      Wisconsin top stories      Arthur levinson      Axel Ullrich      B cells      Clinical research      Dennis Slamon      Emory University School of Medicine      GAVI      Genentech      H. Michael Shepard      HER2      Herceptin      Immunotherapy      Jacques Miller      Lasker Awards      Lasker Foundation      Life Sciences      Max Cooper      National Institute of Allergy and Infectious Diseases      Roche      Ronald Germain      T-cells      Trastuzumab      Walter and Eliza Hall Institute of Medical Research  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Why Menlo Ventures Backed Its First Construction Tech Firm

Why Menlo Ventures Backed Its First Construction Tech Firm

Fieldwire , whose mobile app helps builders and construction crews coordinate their work, announced today it has lined up a total of $33.5 million across two newly disclosed... Read more ...

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

One Texas-based healthcare software business has acquired another in an all-cash deal worth $36.5 million, the companies announced late Monday. Irving, TX-based HMS Holdings... Read more ...

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

Anticipated FABRIC topology at the end of construction. The National Science Foundation is funding a collaborative effort to create a nationwide research infrastructure that... Read more ...

Automated Trucking Company TuSimple Adds $120M More From Investors

Automated Trucking Company TuSimple Adds $120M More From Investors

UPS, the global package delivery giant, took a minority stake this summer in TuSimple, a self-driving trucking company, but didn't reveal financial details. On Tuesday, the San... Read more ...

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Pharmaceuticals, which is testing a new type of drug against life-threatening infections acquired by patients with compromised immune systems, has acquired the rights to... Read more ...

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Denmark's neuroscience-focused pharma firm Lundbeck has agreed to pay $1.95 billion to acquire Seattle-based Alder BioPharmaceuticals to boost its late-stage pipeline and... Read more ...

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

A diagram of the layout and major features of the KATRIN experimental facility at the Karlsruhe Institute of Technology. (Credit: Karlsruhe Institute of Technology) Note: This... Read more ...

INmune Bio Invited to Speak on Company's Advancements in Cancer Treatments...

La Jolla, CA., Sept. 17, 2019 - INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease... Read more ...

Equillium to Host Business Update Call on October 1, 2019

LA JOLLA, Calif., Sept. 17, 2019 - Equillium, Inc. , a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe... Read more ...

AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company's...

SAN DIEGO, Sept. 17, 2019 - AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) , a world leader in cannabinoid research and development, today announced... Read more ...